Barclays PLC decreased its holdings in shares of Avantor, Inc. (NYSE:AVTR – Free Report) by 17.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 536,065 shares of the company’s stock after selling 113,226 shares during the period. Barclays PLC owned approximately 0.08% of Avantor worth $11,332,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Massmutual Trust Co. FSB ADV raised its position in Avantor by 211.2% in the first quarter. Massmutual Trust Co. FSB ADV now owns 1,363 shares of the company’s stock worth $29,000 after acquiring an additional 925 shares in the last quarter. Compagnie Lombard Odier SCmA purchased a new position in shares of Avantor in the 4th quarter valued at about $32,000. Gladius Capital Management LP acquired a new stake in shares of Avantor in the fourth quarter valued at about $36,000. CoreCap Advisors LLC purchased a new stake in Avantor during the fourth quarter worth about $44,000. Finally, Belpointe Asset Management LLC acquired a new position in Avantor during the fourth quarter worth about $58,000. 89.94% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
AVTR has been the topic of several research analyst reports. Royal Bank of Canada boosted their price target on Avantor from $27.00 to $28.00 and gave the stock an “outperform” rating in a research note on Monday, July 31st. Raymond James lowered their target price on Avantor from $28.00 to $25.00 and set an “outperform” rating on the stock in a report on Monday, July 31st. William Blair cut Avantor from an “outperform” rating to a “market perform” rating in a research report on Monday, July 31st. Morgan Stanley decreased their price objective on shares of Avantor from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, July 31st. Finally, Robert W. Baird dropped their target price on shares of Avantor from $24.00 to $22.00 and set an “outperform” rating for the company in a report on Monday, July 31st. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.12.
Avantor Stock Performance
Avantor stock opened at $20.76 on Tuesday. The stock has a fifty day moving average price of $20.60 and a 200 day moving average price of $21.46. The company has a current ratio of 1.61, a quick ratio of 1.04 and a debt-to-equity ratio of 1.11. Avantor, Inc. has a 52 week low of $17.91 and a 52 week high of $29.13. The firm has a market capitalization of $14.03 billion, a P/E ratio of 32.95, a PEG ratio of 3.61 and a beta of 1.31.
Avantor (NYSE:AVTR – Get Free Report) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Avantor had a net margin of 5.89% and a return on equity of 17.00%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the company earned $0.37 EPS. The company’s revenue was down 8.7% compared to the same quarter last year. Equities research analysts anticipate that Avantor, Inc. will post 1.07 earnings per share for the current year.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
See Also
- Five stocks we like better than Avantor
- How to Calculate Return on Investment (ROI)
- 8 Best Meme Stocks to Buy Now
- Why Are Stock Sectors Important to Successful Investing?
- Is Now The Time To Buy XLF Financial ETF?
- Conference Calls and Individual Investors
- Three Ways To Play The Rise In Oil Prices
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
